Welcome back to the Pharmaverse!In this episode our host Michael Pietrack speaks with Isaac Veinbergs, co-founder and chief business officer of Libra Therapeutics. They discuss the company's focus on developing therapeutics for neurodegenerative diseases through the mechanism of autophagy. Isaac shares insights from his career journey, including pivotal moments that shaped his path from academia to biotech. Listen to Veinbergs "We're working on therapeutics for neurological diseases." The conversation also delves into the current fundraising landscape in the pharmaceutical industry, investor hesitancy, and the importance of flexibility and humility in leadership. "If you do the right science, things will all work out fine." Tune in for a great conversation about leadership, neurodegenerative treatments, pivots in Pharma and more! Takeaways🧠 Libra Therapeutics focuses on therapeutics for neurological diseases.💡 Isaac's passion for biotech stems from personal family experiences with dementia.🔄 Transitioning from academia to biotech can be met with skepticism.🎯 Identifying and seizing opportunities is crucial for career advancement.📉 The current fundraising environment is challenging for many biotech companies.📊 Investor hesitancy is influenced by market conditions and lack of recent IPOs.📖 A compelling scientific story can attract investment, even for first-time founders.🗣️ Effective management requires clear communication and goal setting.🌊 Flexibility in leadership is essential to adapt to changing company needs.🙇 Humility is important when transitioning roles within a company.Chapters00:00Introduction to Libra Therapeutics and Its Mission02:58Career Development and Key Pivot Points06:04Transitioning from Science to Business Development09:10Fundraising Landscape in the Pharmaceutical Industry12:14Investor Hesitancy and Optimism14:59Leadership Insights and Flexibility18:07The Importance of Team Dynamics and Humility